ReviewHaematologica2020
Innate immune cells, major protagonists of sickle cell disease pathophysiology.
Review in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Effect of Intradermal Morphine on Histaminergic and Non-Histaminergic Itch: A Randomised, Single-Blinded, Human Study.Experimental dermatology · 2025Trial
- Emerging preclinical evidence supports a potential role for cannabidiol in the management of sickle cell disease.Haematologica · 2026Review
- Sickle red blood cell/Siglec-9 interactions contribute to neutrophil activation in SCD and are associated with survival.Blood. Red cells & iron · 2026Article
- Cytokine and chemokine signatures of steady-state sickle cell disease in African children: a cross-sectional study.BMC immunology · 2026Article
- Newborns with sickle cell trait have distinct peripheral blood molecular signatures across the first week of life.Blood. Red cells & iron · 2026Article
- Apohemoglobin-haptoglobin complex is a therapeutic against vaso-occlusive crisis: scavenging of hemoglobin and heme.Blood advances · 2026Article
- Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions.Immunology · 2026Review
- Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.Blood advances · 2026Article
- The small-molecule Syk inhibitor R788 inhibits hematopoiesis and worsens anemia in sickle cell disease mice.Blood vessels, thrombosis & hemostasis · 2026Article
- Immunopathogenesis of Sickle Cell Disease: Mechanisms of Immune Dysregulation and Clinical Consequences, a Narrative Review.Journal of blood medicine · 2026Review
- Editorial: Unraveling inflammatory pathways in sickle cell disease: molecular, cellular and translational insights.Frontiers in immunology · 2026Article
- IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia.Research square · 2025Article
- The Whole Blood Transcriptomic Analysis in Sickle Cell Disease Reveals RUNX3 as a Potential Marker for Vaso-Occlusive Crises.International journal of molecular sciences · 2025Article
- From old to new: Repurposed drugs in the battle towards curing sickle cell disease.British journal of haematology · 2025Article
- Dynamics of neutrophil phenotype and function in sickle cell disease.Frontiers in immunology · 2025Article
- Monocyte-red blood cell crosstalk supports clearance and heme metabolism in sickle cell anemia.Frontiers in immunology · 2025Article
- Review
- Effect of Unmetabolized Folic Acid on Immunoinflammatory Markers in Sickle Cell Disease Patients Taking Folic Acid Supplementation.Indian journal of clinical biochemistry : IJCB · 2024Article
- Impaired phagocytosis and oxidative respiratory burst activity in sickle cell anemia leukocytes.Journal of Taibah University Medical Sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD), considered the most common monogenic disease worldwide, is a severe hemoglobin disorder. Although the genetic and molecular bases have long been characterized, the pathophysiology remains incompletely elucidated and therapeutic options are limited. It has been increasingly suggested that innate immune cells, including monocytes, neutrophils, invariant natural killer T cells, platelets and mast cells, have a role in promoting inflammation, adhesion and pain in SCD. Here we provide a thorough review of the involvement of these novel, major protagonists in SCD pathophysiology, highlighting recent evidence for innovative therapeutic perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.